N
Google TrendSELMA BLAIR (2000+) — Selma Blair arrested for biting flight attendant, trying to open plane door
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:selma blair2000+al-nassr vs neftchi fergana2000+samantha busch500+peggy flanagan200+sean combs10000+boeing 747500+frank bisignano2000+justin watson500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "BioNTech Clinical Data at" (30 stories)

Top Headline Story

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
Lead StoryBioNTechtech
Mar 24

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPWGpKR0U2YUlUd0hzcHBjQW95b3FJN3Q5YWt5b2lTN1pQYUQzVnNPa3FzRW1rYm1LU0xFTjBwNXJzanl4MkF2RndUeGZwYnVVMEZtLWQ0cFBzOHRKVDVKSk5jQVhmVGNPZ19yOEVpZEZJM0hqZWx6VUwwbGRpbVJuYzAzRkNRRWNRTjloYkRyNEZGT0VPMm1iUHk3SXR6NnRZaVg4UVZObVMtc21DR3hyZUJLMVBqTXJZVG5zMlNpZWJ1Vkg1WU9SSVZTT2g?oc=5" target="_blank">BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer</a>  <font color="#6f6f6f">BioNTech</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+30m ago

selma blair

Selma Blair arrested for biting flight attendant, trying to open plane door

Filter stories
2000+40m ago

al-nassr vs neftchi fergana

Al Nassr Asian Champions League clash in doubt over Riyadh security situation

Filter stories
500+40m ago

samantha busch

Kyle Busch’s Widow Samantha Calls His Death ‘Unfair’ After ‘Emotional’ Celebration for Beloved NASCAR Star

Filter stories
200+40m ago

peggy flanagan

Minnesota Poll: Flanagan holds narrow lead over Tafoya in U.S. Senate race

Filter stories

Search Results for "BioNTech Clinical Data at"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
BioNTech to Present First Lung Cancer Data for Pumitamig-Elfetabart Drozuntecan Combination and Updated Gotistobart Survival Results at WCLC 2026
Quiver Quantitativetech

BioNTech to Present First Lung Cancer Data for Pumitamig-Elfetabart Drozuntecan Combination and Updated Gotistobart Survival Results at WCLC 2026

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxPTVF3aXQzR2g0TFRhNEVyZ0JocmNFUENRWVNCN3pBVkh6cEVvN3k0X1FTSXNfRE9ubFhtd2FKZ21iOHN4aGZQMVZBZ0Vxb1JUN0xkelFDZUtmcWtQbFRablY1b3NoQzNqWVdfSXNlX3N5R29YZHhyRFFwSEVCZ1JxVGFBZW1tNExvYlRmai01TFVLRTVwb3BFX2tvNVBybm5JdUF3Qm5NWm0wYklXdDNodkpNOUNiVFNHOGpsQ1N0MVBabHRCZXFxSWItUUhqOTRyUldfSGszbXMtcVl1WnVacXBHU1c5YlcxanFZaXZpRHlocHdXWWl3SThNdmFpcWcxZ0FzT1ZLa2R6QQ?oc=5" target="_blank">BioNTech to Present First Lung Cancer Data for Pumitamig-Elfetabart Drozuntecan Combination and Updated Gotistobart Survival Results at WCLC 2026</a>  <font color="#6f6f6f">Quiver Quantitative</font>

Read Full StoryMore like this
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
Fierce Biotechtech

BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPOThxMnV4N0N3Y1hLMmEzbWZaanNlSzdpQVFyckt3WFlhRU1rd0wyeURKS1FmcXk1dllmb1VPUnA0UjB4YmgtR1hQOWttVl9mRHZneTFHeGdGVlM2aExidWxIaktMNzNxQ3dMUjBHUWlRNWpkZlJ4aVZpX3ZjY1VvTEt5LUVVVXk5MDVIc25DNWZiMGxiYUpkS202NlRpci1teG5jdExBMDRRTldfLUE?oc=5" target="_blank">BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
BioNTech's lung cancer program has 16 ongoing trials, with new data due in Seoul
Stock Titantech

BioNTech's lung cancer program has 16 ongoing trials, with new data due in Seoul

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNeDNfOFNneFMwUXE2LVJhTHR4SXdETVY0bWVfZm16UnJlampZdGFlTmVQYzFkQVl4b0FoQ3RBU2pTeVBXOW9qNTVITGlnQ1JabndzdExOOVZFV2doVThyZmNaajRSTnlwWUtlYzVXZF84NWRHNngzZDBhc1hTMno5Uk5mMlNCOWFyMDZMSkxhcWY3aXRwN0w1TkZFTDk4elBNMkFZWkxIaXloRWlsaHJIZ0dnU3R3YWU4ZkUwQk1n?oc=5" target="_blank">BioNTech's lung cancer program has 16 ongoing trials, with new data due in Seoul</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
BioNTech (BNTX) Presents New Lung Cancer Data, Is The Stock Already Fully Valued?
Yahoo Financetech

BioNTech (BNTX) Presents New Lung Cancer Data, Is The Stock Already Fully Valued?

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOQWdzQjkwY2NhZzNLaHhnSXdGRjcyVDBKUE1OdXJKZ00xZjNyMmc3MHRPRVNMM1hZNkRrSmRNdnRIbXF6Z2VuSFo3X1hOOG9yd253ZkQ0Q2JCT0lCWHlfRWVCSFdRQTl3cE1DR1o2cFIzeHRMejBtTkx3NnlmczRwTWJ1SGxfSnBaQ1I3VUxuOURkekN0X19RRm1GQQ?oc=5" target="_blank">BioNTech (BNTX) Presents New Lung Cancer Data, Is The Stock Already Fully Valued?</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Business Wiretech

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNWkRLWkdGWWRtT0t1QzFqc3JMWnRmNmJ0NDlkdTBjTExhWFhoQTZ6SG1BdUtjQmJfbWl5ODNkOUNocXRXVGxKQTl4czBaUENmbXZaaXdLbkcycE1kT3NsZW5xTm9uTFlXUE5PcXlHdlFUZnhHdmxJWHNpZHJQeDdBSWd0Qk9MZGtaM1NjeWhrRHhQdzZUOWdYVU43ejY5dzdHN3Q3RngxSnBTZC1BSTJZNk00X1ZTVFdxRTY2cW1iQ2tnWEQtZ0ZsUUZFRUpOMkNV?oc=5" target="_blank">Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
BioNTech cancer vaccine trial halted after survival imbalance
European Biotechnology Magazinetech

BioNTech cancer vaccine trial halted after survival imbalance

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPd2JWbDRLR2JoMmZZZGdZNGJPT3lHTXFmc0Z2NUF6SFh6OFBPSUJUeGhydXdJd1Z2b1JjT3NDblM5aWxwR1NldkFKTUw3TDhLSzFOenZXcElpbkdqSkZZdHRhcG5CSXk5U0FlR05mb1RaSWFXdk12SlJiNWpVRHJ2alp3RU5CYzYzZlFRM1NCZS1LZzQ4elk2bjdtY2VTdFlaUjd0Wk9zOG9MRWhndlE?oc=5" target="_blank">BioNTech cancer vaccine trial halted after survival imbalance</a>  <font color="#6f6f6f">European Biotechnology Magazine</font>

Read Full StoryMore like this
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
Clinical Trials Arenatech

BioNTech and DualityBio report positive data for trastuzumab pamirtecan

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQTWxrSHB1eGJ2djRvUk9zSTRMQzZ4Ukdxa2kxSmZsZlp5cjZkMWJQWUt2VWRwSDg1b0VmZkRfU0ZLWThyT2tkZUZKbm91XzRPaXlqSm5PRl95dkkyeTBldEREQ3M5SXBDSnptUDhFQWJLbzFra0NDSzFSeE5XTVpvajJIYk1xZXd1eHNrMw?oc=5" target="_blank">BioNTech and DualityBio report positive data for trastuzumab pamirtecan</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
STATtech

BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxONGVaY2pmRVRjYmZwSEFQeGRCWmtjUlZYRXNIbkk0ZEZkYWc2QzVoX0dUQ3FxVVRjaFFRQ1RXcEJYN0JJbzUyNUw2UEVUbjBkQ0pJdkw2SGlLNXZfQ25IbVVXS3BPZmhYVy1VR1o3elpOLTN6SEVJeU1ndEF4Vjl1RjZxcFk3X1JCM0VwVGI0M2M?oc=5" target="_blank">BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
BioNTech (BNTX) Q2 2026 Earnings Call Transcript
The Globe and Mailtech

BioNTech (BNTX) Q2 2026 Earnings Call Transcript

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPQzBveE92T2VYbjJrQmxfM1otdWVfa25TQlctVHZxd2VMYy01WDB2R1JZQl8wbFdDV0hIWXhrQWpqV2xrVnhyTWJtRllMN1hQZGdFNnNLcUJ1OHg0bHp6ZjJaUUNjS3V3LVZfTEd4TzBma295S3dsekZ2ZnVDOTZTSWN3UWhXMVdvTEpVdUQ1RHpMWTMwLU1CSmU5d3lCTV9FdXUxTDYzYjdWQ2xPbzV2LXhnOVNtcmdIUDhPaWNsNFhFem9iWXpYLTNB?oc=5" target="_blank">BioNTech (BNTX) Q2 2026 Earnings Call Transcript</a>  <font color="#6f6f6f">The Globe and Mail</font>

Read Full StoryMore like this
ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach
Fierce Biotechtech

ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOVkI2bmZhMUxJOEZKWGdmOW9DVHJOYmJJRk5sSEJTN216dmN5d2VGdG9TZGRTS01PQUJqUG9jVGF3U0RiSXpFSG5kUUdmMHU0M1dOZm90VkJaMHAza19PR3JlMXlvb3pSSWhQMV9kdGU1V0VMYm9ldThDQnNnUnM3WTVNNFhFdTdIbzN2OTdUNVM4R3RWblEyTmp1TW9acThjb05uemp1bW1SSlZ3c3QyYml5aw?oc=5" target="_blank">ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
BioNTech Unveils Promising Clinical Data for Pumitamig and Gotistobart at ASCO 2026
Quiver Quantitativetech

BioNTech Unveils Promising Clinical Data for Pumitamig and Gotistobart at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOSFFMRWhuYmM4YkpJMkNrUUhlWk13UGpqMVdaWTNzRlB2QUJzUkEtdi1CUU9HRWl4TTBDbk01MFpiWkYtQkpZS1Rid0VzblBBWnZNRUJOemdCckVOZXc2VzdGdmRBVG1ZWE5tNmRSNC0zRFEyaUp1dmpfNW90Rm5jdFJNbEVxREdNZk41NzhUTFlUVElld1MtOHRVZy1xZXlicG9LM2R1WUlySGkxLUVIOGpCeEJtLUU?oc=5" target="_blank">BioNTech Unveils Promising Clinical Data for Pumitamig and Gotistobart at ASCO 2026</a>  <font color="#6f6f6f">Quiver Quantitative</font>

Read Full StoryMore like this
BioNTech reports promising Phase II data for uterine cancer ADC
European Biotechnology Magazinetech

BioNTech reports promising Phase II data for uterine cancer ADC

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQcUc2N0NfTGZMSlgtdVBkQVUwdUxFSVdQLVFMN1pSUlh1dW1NN3VQUlEwTHZNYnJ3QmpJQTUza24zNzY4VFRJeFlRbDJzOWFsUjQ1aHVGV0lwOVRkWjQycWFTMlpmb0gxNnIwMjhtQjJHZkZLWmM5b0FsZUhtUGdURmFPclc3NW45RmpnaE5CcHp6WFQ3WjVtMktOLTVMN05rM3RCTE5HcXBXMFphQVFqaQ?oc=5" target="_blank">BioNTech reports promising Phase II data for uterine cancer ADC</a>  <font color="#6f6f6f">European Biotechnology Magazine</font>

Read Full StoryMore like this
JPM26: BioNTech gears up for multiproduct oncology status by 2030
Clinical Trials Arenatech

JPM26: BioNTech gears up for multiproduct oncology status by 2030

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMThVOUxXTXV1Q09uT040NzNZVG8wd19BR0lHdmk2NUlmTWJ6a0E5OThCZlNqcTVHbnVvdGVyQmZwRl9mbXdYaDFCVzc5ZkFyV1dnOG9zdmw2aEpBM2FoekZUdTUtZFh5Q1RzT3RFZ0g5S243c2FLWUkyQjU2RF9oN2QxX0diclZsQjFUWEhKWm9yV3g3UHJOcW00N1J2R1pjclVvNE9KT01XQQ?oc=5" target="_blank">JPM26: BioNTech gears up for multiproduct oncology status by 2030</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
Fierce Biotechtech

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOMTZoNS1GV2xtLTRZR1dMMGN1cU5oMk1vWGdKLVU4dXdmYTE4eXNxa3VlRHJ4LVh3SUZMNVFBcmp0SUN1ZU51TWhBb29NdTE5QzM4LXpkb3gyNURUNGw3UjZWMGNnQllfb0FZM1pBMURDeFBuNjVNYUFQMTNWVmRaTzdqYkJBZGJweVRxNXRMT3hVcXhyZG9UYzA0MnNuSG5rYW14QWFvQk1sTThO?oc=5" target="_blank">BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
BioNTech (BNTX) halts colorectal cancer trial after safety board review
Stock Titantech

BioNTech (BNTX) halts colorectal cancer trial after safety board review

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPeDZJVXpVdjdVR1o5UzFDVnVTT1VrdF9SNHZJdlozUDZjQWdlVllUXzd4YjFhX2syNE1reDRMTndKQVI5THJlYVd2bS1EZUtudXNtMUw3UnVPWUFUN3cySXdfSTVtY3BhYXRmc1NINUJBVkhhQkN1RURQMzYwR0N0NTllUUVnNUt1OTlOY19GZXRaU0dMa3ZfM0xxbHgxTl9yS0ctUDlyejZxdDFYb0E?oc=5" target="_blank">BioNTech (BNTX) halts colorectal cancer trial after safety board review</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
Fierce Biotechtech

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOc0JuT3ZTUVhMMGo1ZFRYYW44YXdGczJaTVZtMUtwVFV6RllfQ3NYS01VRjBZTTRfV1NsNjllNzJlX2dsd0Q3MHg4RV9XWXNuWXIzdXI5YmhfTHRsNTJaajNDVHRMeERZQjd6Q184ZUgxdWJFbVBnaDZfUkpld19kZzZaTnVaSk40UFdHSEVCczBlOWpHdVlDeXBzbHhWenVUQXJNbURrWjF3TTJvR2hvb2d3?oc=5" target="_blank">BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
2026: A year of reckoning for BioNTech
European Biotechnology Magazinetech

2026: A year of reckoning for BioNTech

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxObnQ2N2tMczNqeldLNDFIYTdRN2tNbGVOSl9ONHdFMTdSRjI2R2E0TVlyMWR3U3NveHVyWU1WSy12RFpuaDhDY3hTUEpRQ3ppLVBoZ0Z6MnB6eXVEdzlrTzVHWlV1YkVSUTZjaEpMWHk4RVZXajJGaE9NSlhMTUJ2eG1PaVl1TjlhWk85MUxR?oc=5" target="_blank">2026: A year of reckoning for BioNTech</a>  <font color="#6f6f6f">European Biotechnology Magazine</font>

Read Full StoryMore like this
EU Authorizes Pfizer-BioNTech XFG COVID-19 Vaccine for 2026-2027
The Clinical Trial Vanguardtech

EU Authorizes Pfizer-BioNTech XFG COVID-19 Vaccine for 2026-2027

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQV2xFcDd4bmxGTExjVUJwbFdSRC0zVEhzVV8wVl9ydndHQll6UTlZdUFsaGxhd3JpbmVUUTllMmdXOEJiNUlWOHNqck9ZYmMyWkFYZTlSeWJNM3B4eUNRU0ZmT1dFUVRibWFVZTZYTkxGVWROS3JkTFFPeW9waDlKSzR3QTQxUHVCSkdGcjZFVlEtVk1XUlJJZS1mdFFZRnRoRUV6VTlzYlpadzBs?oc=5" target="_blank">EU Authorizes Pfizer-BioNTech XFG COVID-19 Vaccine for 2026-2027</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
Personalized mRNA Cancer Vaccine Gives TNBC Patients Strong Multi-Year Response
Inside Precision Medicinegeneral

Personalized mRNA Cancer Vaccine Gives TNBC Patients Strong Multi-Year Response

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxORHBEQ0NVYWpWRDkyNWJlelFqOVFScC0xamdnZ3dvSmc0eXF3Tl9CVE9xdUVHTm1TQnFoTkdMZ2ptcjBhNklSenJ6dE9PZ0JoUk1uTmF0LXdBRllOa1M3ZzB6NUotV1RkemNSb1h4a180N01zQURFUURnQ0hGTWJJMnRuMW5BZm1LbWhSSDEzYzRPYVZxdDBwLU5MNmNBaWtPTndXcEdwb1JJTGljaFlySVJQR2hlY0J5OUNvQl9KRnlmYndsajhkU01WTmNFT1o1VDRpT0VIQ1dXVkg1Sl8w?oc=5" target="_blank">Personalized mRNA Cancer Vaccine Gives TNBC Patients Strong Multi-Year Response</a>  <font color="#6f6f6f">Inside Precision Medicine</font>

Read Full StoryMore like this
EXCLUSIVE: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Reuterstech

EXCLUSIVE: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPd0tQZXdkRHJPR056VUVHUWU1VzJaVWxDNUNQaWxaRTRkTHJkenBLYnZwS3MyRl8zZ0NDaFpjTDBCV1BnY013SDdNdmtCWmdxUzRWQS1LUjJad1paY18tRlZGWEtzWFRaa0pobXBtdml3WnhyUEc5ZlRmTWl3YW84WWxBZlhTUnlzSGswcDQtdjdxWjJiT0g3S3ppS05JbDBVMXI1ODRLdjgzT2g0Q3RKa1NqUHMxRGs1OFpmSUcyZ2NFSm5BT2lGbmMxa2xTakFXbFpvMzdDTm5FZU0?oc=5" target="_blank">EXCLUSIVE: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
In Brief: Strong Results Advance DualityBio/BioNTech’s B7H3 ADC Into Phase III CRPC Trial
Scriptech

In Brief: Strong Results Advance DualityBio/BioNTech’s B7H3 ADC Into Phase III CRPC Trial

<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxOMTBVWW9kOXBwcjFZdERfTVNlZ2duUC1ycUR3cndjeTNnRTZOM0p2R3JRSE9NQ0k1UVZWTXl1djR4MndfbFhzdFFYWWlGcWVJUWRDVDJtd21pcmV4ZzhtZXpremlpV21mdm1aX3VvcDJaeGNGbk9NZm5USURUblNPRHNPb3Q3QlNtbHl4UXRjclNfYkYzNDhsS21UMUpCWUtoWDB2cjJpNHV6WHZVaEU2Rl9tQmd6a2lJTEZPbTVMd2FpcWRFa0FMM3pDOGFPaExMWDBaZlFSbEhxZURPc1Nwakd3UW5XamZaQXRObDcyS1hxWEIzdWZOaXdrSzA0Q3JjZzRFbQ?oc=5" target="_blank">In Brief: Strong Results Advance DualityBio/BioNTech’s B7H3 ADC Into Phase III CRPC Trial</a>  <font color="#6f6f6f">Scrip</font>

Read Full StoryMore like this
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge
Fierce Biotechtech

BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOSHFyS3EwQ3ZaNnlscnJjanl1SFlSdTZiWlVIam1udW5jUE5ZMkFPelJ5UTh0YkNyNDFyYVUwdHdoVEU0N1drQndaM2VhUUU1cjVnNDlHTGJFUllkZFIyVWZuamJpVnh0YlVWcHNwWEZkNS1oMWdtQWVJTnBlcW1pX3B4amU3M2hQV2ZET1I0WUxjeU5nZUJlWVZLcXhKRjBSMjRuVV9VQ3VSWlhxSUZMNm95MXdZbHQ4TndrSng4WS16eGlDLVE?oc=5" target="_blank">BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
EU Authorizes Pfizer-BioNTech COVID Vaccine for Ages 6 Months+
Stock Titantech

EU Authorizes Pfizer-BioNTech COVID Vaccine for Ages 6 Months+

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUF82R0stX0d6QVBNT3E1MzRDekRyUVFRVlJuUWNVenI0WXF3TW1fcDZHOEJHaVQzc3BGNzFjN3VMcFIwRVNpVThTa3EzTkxmXy1uZXpmb3hVUHR5YTIwNl83V3YwN3FrUVhzM0RSN2RXanY4bldWUi1kTzZ4dzVUTTMyaHdSNHlLOE1PWkhpdWZrMTkwOXFkdENGSTlDdURPYzZoMDhUVmZiUFdCWFpiQnc1U0c2d0pGQzk0?oc=5" target="_blank">EU Authorizes Pfizer-BioNTech COVID Vaccine for Ages 6 Months+</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Business Wiretech

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQLUt1YmNONms4eFlPcUFiajJhMjQ2MWN6OGtNNHRkNlZ6WU1aeTdoY25LY0k2aUNXRFdVQzJyTFdONVY5aGppaGk1bE4yNjFJQUNpWDRHRE1VR3pzdWdlWHluSXpoOVZLWkN2dVZZdDZBOG5jQU55elR1SGJxUEhfZDF3bE1XTGtZMFB3YnNQRjRVMXF4NE9FT1R3TDFCZ1Z0Nzg0WWM1c0c1TXdKblNLU0M4bXhYVC02U1RPNmg0RE1EM21ITWJhSEZpZGlZOEQtU2NSc21qTEF2QnVmV2JnbjNlbzlXbUhZQk5JME5Saw?oc=5" target="_blank">European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
The Manila Timestech

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

<a href="https://news.google.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?oc=5" target="_blank">BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients</a>  <font color="#6f6f6f">The Manila Times</font>

Read Full StoryMore like this
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
Fierce Biotechtech

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPS3BsWmhjQmI3S2taS1prOTZSNkV0LUR1a01wbEctejl3RjRZYWJmTEs0NUd2bzhHUUVxV0JnZG5rRm5zMXNuWVJIblY4YUxlVS1OQXR6Qk14b2lCVkNLZ1dLU3I0YUU4TUROeG9pa2NUcTVXamZ1VlBNa2lZR1NRYkRfOGNnUERjbFRRc0tvbEEwTWhUdmJ0djZFOEJZckNYVTJncG1YMk5CazhxbzdPMHIzOW1pajR3?oc=5" target="_blank">BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
BioNTech's Leadership Handover Sets the Stage for a Pivotal September in Seoul
AD HOC NEWStech

BioNTech's Leadership Handover Sets the Stage for a Pivotal September in Seoul

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPU2ZzLVI0VDI5NGZpaTFZeEx0cm54ZTJrcEZwbE1GVnNsNGpFTm5mSVM5RXViY2hoTkt5YVdIYzdtaEV0eVNKU2Vydk5LdG9SQlEzeG8wZWxBOGpJTDM2aXY2TElzLXJ0Z0lxUDF1dktPWV81S2ttMnZRTG5Ja2ZjLWc1RWZKTEJVZUNXYnhpbm1JRVZfR1JLTWVVbEIyMVN5YzExX0ZDei1WVTVyaGhfREZ1YnY1SmJIZnRKVXpUZWs0WlhCbGxvc2J1QnNWUjN1di1lT0QxZkJlQUht?oc=5" target="_blank">BioNTech's Leadership Handover Sets the Stage for a Pivotal September in Seoul</a>  <font color="#6f6f6f">AD HOC NEWS</font>

Read Full StoryMore like this
BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer
Fierce Biotechtech

BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOLU9IVDRQaXZpUVRwSUtYOHp3cHkxSWQ5cm5ENlNVekNPWGhSQWRLMEtYVG9GX1hWa0JqNk1FNnJJRm1SZ1duUE5jOUhxTUIwZW5YUmpwUkFhN1lyc3JNU2pfQ25CdlZROUN5LWFaX09JZWpCMHZEODhGQU1sd2RFWC1sUVNqSjBJclliVTZrbzNJWVFsSVJtTlFMdUM3ZjlmNERmREhGQXVNdjVxYUF2VW5rT0lMMnliOV9Zcm5sM2E?oc=5" target="_blank">BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
BioNTech's Sympathy Rally: When a Rival's Success Becomes Your Stock's Best Catalyst
AD HOC NEWStech

BioNTech's Sympathy Rally: When a Rival's Success Becomes Your Stock's Best Catalyst

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNd2wzWExpU2tDazhGYVUwME1YZ2RiX0MwX09Zd0pWaHphMkxISzNhWmlPTjNHUW1UQlpEX3pUTHlGTEo5XzN1LWVTd3p6bE4zWW5lRUE4ZWVDdlBQVVljS3NuZ2ZPcUk0TE1SOEl6VGxLcmpXUmNFMThRSEJVWXUzU3pvWTdWeUVqWWZ3Sk5SQzhLbUlFNHdSSnIxaTJuRHA3MnpnaUl0ODI1MzBPMlBDNDJidmJMUFg2akZMa3AxUncxYUhrS2hvRmRiS2Q3UUxSOHFCcEhodWo?oc=5" target="_blank">BioNTech's Sympathy Rally: When a Rival's Success Becomes Your Stock's Best Catalyst</a>  <font color="#6f6f6f">AD HOC NEWS</font>

Read Full StoryMore like this
"BioNTech Clinical Data at" — Live Google News Trends & Headlines